To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC76830 | DG013B formate |
DG013B formate is an epimer of DG013A.
More description
|
|
| DC76829 | DG013B |
DG013B is an epimer of DG013A.
More description
|
|
| DC76828 | DG013A formate |
DG013A (formate) is a phosphinic acid tripeptide mimetic inhibitor. DG013A (formate) displays significantly weak affinity for both ERAP1 (IC50=33 nM) and ERAP2 (IC50=11 nM). DG013A (formate) can be used for the research of autoimmune disease and cancer.
More description
|
|
| DC76827 | BDM_92499 |
BDM_92499 is a nanomolar selective IRAP inhibitor, with an IC50 of 3.4 nM. BDM_92499 also inhibits ERAP1 and ERAP2, with IC50 values of 0.46 μM and 4.2 μM, respectively.
More description
|
|
| DC76826 | Arphamenine A |
Arphamenine A is an aminopeptidase B inhibitor found in Chromobacteriuin violaceum HMG361-CF4. Arphamenine A can inhibit the activity of aminopeptidase B, and can inhibit sarcoma 180 and invasive micropapillary carcinoma (IMC) cancer.
More description
|
|
| DC76825 | Apstatin TFA |
Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection.
More description
|
|
| DC76824 | WF-3681 |
WF-3681 (compound 1) is an aldose reductase inhibitor and a fungal metabolite.
More description
|
|
| DC76823 | RJG-2051 |
RJG-2051 is a selective covalent aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor with an IC50 value of 13 nM. RJG-2051 interferes with the metabolic process of substrates such as androgens, estrogens, and prostaglandins by AKR1C3. RJG-2051 is promising for research of cancers.
More description
|
|
| DC76822 | M79175 |
M79175 is an aldose reductase inhibitor that can be used in the study of early diabetic retinopathy.
More description
|
|
| DC76821 | (Rac)-Fidarestat |
(Rac)-Fidarestat ((Rac)-SNK 860) is the racemate of Fidarestat-resistant hepatitis B.
More description
|
|
| DC76820 | Mirivadelgat |
Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers.
More description
|
|
| DC76819 | DG 381B |
DG 381B (compound 62) is a 11β-HSD1 and 11β-HSD2inhibitor.
More description
|
|
| DC76818 | ZQMT-10 |
ZQMT-10 is an orally active and potent antagonist of TRPA1, with the Kd of 1.04 μM. ZQMT-10 plays an important role in cancer research.
More description
|
|
| DC76816 | Davasaicin |
Davasaicin (KR 25018), Capsaicin derivative and a δ-opioid receptor agonist. AZ 12488024 is available for research into major depressive disorder.
More description
|
|
| DC76815 | CMP233 |
CMP233 is a potent antagonist of TRPM4, with the IC50 of 0.15 μM. CMP233 plays an important role in neurodegenerative disorders research.
More description
|
|
| DC76814 | (S)-AMG-628 |
(S)-AMG-628 (Compound 16q) is the S-isomer of AMG-628. (S)-AMG-628 is the orally active antagonist for TRPV1, that inhibits the Capsaicin- and acid-induced Ca2+-influx with IC50 of 7 nM and 5 nM in CHO cell. (S)-AMG-628 ameliorates Capsaicin-induced rats flinching, and reverses the thermal hypersensitivity in CFA-induced inflammatory pain models.
More description
|
|
| DC76813 | Zilvetrigine |
Zilvetrigine is a sodium channel blocker. Zilvetrigine can be used as analgesics.
More description
|
|
| DC76812 | Quinacainol dihydrochloride |
Quinacainol dihydrochloride (PK 10139 dihydrochloride) is the dihydrochloride salt form of Quinacainol.
More description
|
|
| DC76811 | Olisutrigine bromide |
Olisutrigine bromide is a sodium channel blocker, which can be used as analgesics.
More description
|
|
| DC76810 | N-Hydroxy riluzole |
N-Hydroxy riluzole is a metabolite of the antiglutamatergic agent Riluzole.
More description
|
|
| DC76809 | ETD001 |
ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis.
More description
|
|
| DC76808 | ErSO-TFPy |
ErSO-TFPy activates the sodium channel TRPM4, causes an imbalance of intracellular calcium and sodium ions. ErSO-TFPy exhibits low nanomolar cytotoxicity in ERα+ breast cancer cell lines (IC50 = 5-25 nM) through induction of necrosis. ErSO-TFPy exhbits antitumor efficacy in mouse models.
More description
|
|
| DC76807 | DAPI |
DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment.
More description
|
|
| DC76806 | CL-424032 |
CL-424032 is a sodium channel inhibitor.
More description
|
|
| DC76805 | CAY10568 |
CAY10568 is a compound based on QX-314 and a linker. MC-PEG2-VA-PAB-Exatecan can be used for synthesis of ADCs.
More description
|
|
| DC76804 | 10,11-Dihydroxycarbamazepine |
10,11-Dihydroxycarbamazepine is a metabolite of the anticonvulsant Carbamazepine. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker.
More description
|
|
| DC76803 | (R)-(+)-Bupivacaine hydrochloride |
(R)-(+)-Bupivacaine hydrochloride is a voltage-gated sodium channel inhibitor. (R)-(+)-Bupivacaine hydrochloride can selectively block the voltage-gated sodium channels on nerve cell membranes, inhibit the influx of sodium ions, and thus prevent the generation and conduction of nerve impulses, exerting local anesthetic activity. (R)-(+)-Bupivacaine hydrochloride can be used in research of acute pains.
More description
|
|
| DC76802 | rel-Licogliflozin |
rel-Licogliflozin is a relative configuration of Licogliflozin.
More description
|
|
| DC76801 | Olorigliflozin |
Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects.
More description
|
|
| DC76800 | Pantoprazole sulfone |
Pantoprazole sulfone is a metabolite of the gastric H+/K+ ATPase pump inhibitor Pantoprazole. AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research.
More description
|
|